Patents by Inventor Shengli CAI

Shengli CAI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSAGE REGIMEN OF MDM2 INHIBITOR FOR TREATING CANCERS
    Publication number: 20220071975
    Abstract: The present invention provides a method for treating a cancer in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject according to a specific dosage regimen and a pharmaceutical composition for use in treating a cancer according to the dosage regimen. The present invention also provides a method for treating liposarcoma in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject and a pharmaceutical composition for use in treating liposarcoma, comprising the MDM2 inhibitor.
    Type: Application
    Filed: May 18, 2021
    Publication date: March 10, 2022
    Inventors: Ngai-chiu Archie TSE, Shengli CAI
  • Dosage regimen of MDM2 inhibitor for treating cancers
    Patent number: 11058673
    Abstract: The present invention provides a method for treating a cancer in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject according to a specific dosage regimen and a pharmaceutical composition for use in treating a cancer according to the dosage regimen. The present invention also provides a method for treating liposarcoma in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject and a pharmaceutical composition for use in treating liposarcoma, comprising the MDM2 inhibitor.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: July 13, 2021
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Ngai-chiu Archie Tse, Shengli Cai
  • DOSAGE REGIMEN OF MDM2 INHIBITOR FOR TREATING CANCERS
    Publication number: 20190201386
    Abstract: The present invention provides a method for treating a cancer in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject according to a specific dosage regimen and a pharmaceutical composition for use in treating a cancer according to the dosage regimen. The present invention also provides a method for treating liposarcoma in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject and a pharmaceutical composition for use in treating liposarcoma, comprising the MDM2 inhibitor.
    Type: Application
    Filed: March 6, 2019
    Publication date: July 4, 2019
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ngai-chiu Archie TSE, Shengli CAI
  • DOSAGE REGIMEN OF MDM2 INHIBITOR FOR TREATING CANCERS
    Publication number: 20180296547
    Abstract: The present invention provides a method for treating a cancer in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject according to a specific dosage regimen and a pharmaceutical composition for use in treating a cancer according to the dosage regimen. The present invention also provides a method for treating liposarcoma in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject and a pharmaceutical composition for use in treating liposarcoma, comprising the MDM2 inhibitor.
    Type: Application
    Filed: October 21, 2016
    Publication date: October 18, 2018
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ngai-chiu Archie TSE, Shengli CAI